180 related articles for article (PubMed ID: 27502594)
1. Significance of EZH2 expression in canine mammary tumors.
Choi HJ; Jang S; Ryu JE; Lee HJ; Lee HB; Ahn WS; Kim HJ; Lee HJ; Lee HJ; Gong GY; Son WC
BMC Vet Res; 2016 Aug; 12(1):164. PubMed ID: 27502594
[TBL] [Abstract][Full Text] [Related]
2. EZH2 Expression in Naturally Occurring Canine Tumors.
Choi HJ; Lee HB; Park HK; Cho SM; Han HJ; Lee SJ; Lee JY; Nam SJ; Cho EH; Son WC
Comp Med; 2018 Apr; 68(2):148-155. PubMed ID: 29663940
[TBL] [Abstract][Full Text] [Related]
3. The histone methyltransferase EZH2 promotes mammary stem and luminal progenitor cell expansion, metastasis and inhibits estrogen receptor-positive cellular differentiation in a model of basal breast cancer.
Wu J; Crowe DL
Oncol Rep; 2015 Jul; 34(1):455-60. PubMed ID: 25998860
[TBL] [Abstract][Full Text] [Related]
4. Ezh2 promotes mammary tumor initiation through epigenetic regulation of the Wnt and mTORC1 signaling pathways.
Liu L; Xiao B; Hirukawa A; Smith HW; Zuo D; Sanguin-Gendreau V; McCaffrey L; Nam AJ; Muller WJ
Proc Natl Acad Sci U S A; 2023 Aug; 120(33):e2303010120. PubMed ID: 37549258
[TBL] [Abstract][Full Text] [Related]
5. Carcinogenic roles and therapeutic effects of EZH2 in gynecological cancers.
Wan Z; Jiang H; Li L; Zhu S; Hou J; Yu Y
Bioorg Med Chem; 2020 Apr; 28(7):115379. PubMed ID: 32098708
[TBL] [Abstract][Full Text] [Related]
6. BRCA1 and EZH2 cooperate in regulation of prostate cancer stem cell phenotype.
Gorodetska I; Lukiyanchuk V; Peitzsch C; Kozeretska I; Dubrovska A
Int J Cancer; 2019 Dec; 145(11):2974-2985. PubMed ID: 30968962
[TBL] [Abstract][Full Text] [Related]
7. Epigenetic regulation of cancer biology and anti-tumor immunity by EZH2.
Christofides A; Karantanos T; Bardhan K; Boussiotis VA
Oncotarget; 2016 Dec; 7(51):85624-85640. PubMed ID: 27793053
[TBL] [Abstract][Full Text] [Related]
8. Role of EZH2 in cancer stem cells: from biological insight to a therapeutic target.
Wen Y; Cai J; Hou Y; Huang Z; Wang Z
Oncotarget; 2017 Jun; 8(23):37974-37990. PubMed ID: 28415635
[TBL] [Abstract][Full Text] [Related]
9. Multifaceted role of the polycomb-group gene EZH2 in hematological malignancies.
Sashida G; Iwama A
Int J Hematol; 2017 Jan; 105(1):23-30. PubMed ID: 27830540
[TBL] [Abstract][Full Text] [Related]
10. Metastatic canine mammary carcinomas can be identified by a gene expression profile that partly overlaps with human breast cancer profiles.
Klopfleisch R; Lenze D; Hummel M; Gruber AD
BMC Cancer; 2010 Nov; 10():618. PubMed ID: 21062462
[TBL] [Abstract][Full Text] [Related]
11. Poorly differentiated breast carcinoma is associated with increased expression of the human polycomb group EZH2 gene.
Raaphorst FM; Meijer CJ; Fieret E; Blokzijl T; Mommers E; Buerger H; Packeisen J; Sewalt RA; Otte AP; van Diest PJ
Neoplasia; 2003; 5(6):481-8. PubMed ID: 14965441
[TBL] [Abstract][Full Text] [Related]
12. ZMYND8 preferentially binds phosphorylated EZH2 to promote a PRC2-dependent to -independent function switch in hypoxia-inducible factor-activated cancer.
Tang B; Sun R; Wang D; Sheng H; Wei T; Wang L; Zhang J; Ho TH; Yang L; Wei Q; Huang H
Proc Natl Acad Sci U S A; 2021 Feb; 118(8):. PubMed ID: 33593912
[TBL] [Abstract][Full Text] [Related]
13. HEPACAM1 and 2 are differentially regulated in canine mammary adenomas and carcinomas and its lymph node metastases.
Klopfleisch R; Klose P; da Costa A; Brunnberg L; Gruber AD
BMC Vet Res; 2010 Mar; 6():15. PubMed ID: 20226097
[TBL] [Abstract][Full Text] [Related]
14. EZH2-mediated Puma gene repression regulates non-small cell lung cancer cell proliferation and cisplatin-induced apoptosis.
Liu H; Li W; Yu X; Gao F; Duan Z; Ma X; Tan S; Yuan Y; Liu L; Wang J; Zhou X; Yang Y
Oncotarget; 2016 Aug; 7(35):56338-56354. PubMed ID: 27472460
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemical vascular factor expression in canine inflammatory mammary carcinoma.
Camacho L; Peña L; Gil AG; Martín-Ruiz A; Dunner S; Illera JC
Vet Pathol; 2014 Jul; 51(4):737-48. PubMed ID: 24048323
[TBL] [Abstract][Full Text] [Related]
16. Oncogenic Deregulation of EZH2 as an Opportunity for Targeted Therapy in Lung Cancer.
Zhang H; Qi J; Reyes JM; Li L; Rao PK; Li F; Lin CY; Perry JA; Lawlor MA; Federation A; De Raedt T; Li YY; Liu Y; Duarte MA; Zhang Y; Herter-Sprie GS; Kikuchi E; Carretero J; Perou CM; Reibel JB; Paulk J; Bronson RT; Watanabe H; Brainson CF; Kim CF; Hammerman PS; Brown M; Cichowski K; Long H; Bradner JE; Wong KK
Cancer Discov; 2016 Sep; 6(9):1006-21. PubMed ID: 27312177
[TBL] [Abstract][Full Text] [Related]
17. EZH1/2 function mostly within canonical PRC2 and exhibit proliferation-dependent redundancy that shapes mutational signatures in cancer.
Wassef M; Luscan A; Aflaki S; Zielinski D; Jansen PWTC; Baymaz HI; Battistella A; Kersouani C; Servant N; Wallace MR; Romero P; Kosmider O; Just PA; Hivelin M; Jacques S; Vincent-Salomon A; Vermeulen M; Vidaud M; Pasmant E; Margueron R
Proc Natl Acad Sci U S A; 2019 Mar; 116(13):6075-6080. PubMed ID: 30867289
[TBL] [Abstract][Full Text] [Related]
18. Polyploid giant cancer cells, EZH2 and Myc upregulation in mammary epithelial cells infected with high-risk human cytomegalovirus.
Nehme Z; Pasquereau S; Haidar Ahmad S; El Baba R; Herbein G
EBioMedicine; 2022 Jun; 80():104056. PubMed ID: 35596973
[TBL] [Abstract][Full Text] [Related]
19. EZH2-mediated Epigenetic Silencing of miR-29/miR-30 targets LOXL4 and contributes to Tumorigenesis, Metastasis, and Immune Microenvironment Remodeling in Breast Cancer.
Yin H; Wang Y; Wu Y; Zhang X; Zhang X; Liu J; Wang T; Fan J; Sun J; Yang A; Zhang R
Theranostics; 2020; 10(19):8494-8512. PubMed ID: 32754259
[TBL] [Abstract][Full Text] [Related]
20. Functional and therapeutic significance of EZH2 in urological cancers.
Liu X; Wu Q; Li L
Oncotarget; 2017 Jun; 8(23):38044-38055. PubMed ID: 28410242
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
